New hope for tough lymphoma: experimental drug IMV101 enters human testing

NCT ID NCT07376642

Recruiting now Disease control Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called IMV101 in 30 adults whose B-cell non-Hodgkin lymphoma has returned or not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive the drug alone, and researchers will monitor side effects and how well the cancer responds.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

Beijing GoBroad Boren Hospital
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 100070, China
Cancer Hospital Chinese Academy of Medical Sciences
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 100020, China
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310009, China
Zhengzhou Yihe Hospital
RECRUITING

Zhengzhou, Henan, 450047, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.